S. Forese and A. Ochsenbien, Les anticorps monoclonaux dans le traitement du cancer, Forum Med Suisse, vol.8, issue.9, pp.160-165, 2008.

G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-502, 1975.
DOI : 10.1038/256495a0

J. Bach, Les anticorps monoclonaux th??rapeutiques, Annales Pharmaceutiques Fran??aises, vol.64, issue.5, pp.308-311, 2006.
DOI : 10.1016/S0003-4509(06)75323-8

G. Paintaud, M. Divine, and P. Lechat, Anticorps monoclonaux ?? usage th??rapeutique : sp??cificit??s du d??veloppement clinique, ??valuation par les agences, suivi de la tol??rance ?? long terme, Th??rapie, vol.67, issue.4, pp.319-327, 2012.
DOI : 10.2515/therapie/2012043

C. Gennigens, J. Collignon, G. Jerusalem, G. Rorive, and A. , Anticorps monoclonaux à usage thérapeutique en hémato-oncologie : généralités, Rev Med Liège, vol.64, pp.5-6, 2009.

A. Maillet, Thèse : Effet thérapeutique du cétuximab administré par aérosol dans un modèle animal de tumeur broncho-pulmonaire. Importance du récepteur FcRn dans la réponse anti-tumorale à cet anticorps, 2008.

A. Scheen, Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Med Liège, vol.64, pp.5-6, 2009.

T. Lecomte, A. Payancé, A. Aubourg, H. Watier, and G. Paintaud, Les anticorps monoclonaux thérapeutiques : une classe médicamenteuse majeure en pathologie digestive, HEPATO-GASTRO et Oncologie digestive, 2012.

K. Bouzid, N. Bedairia, and M. M. , Anticorps monoclonaux th??rapeutiques en canc??rologie, Pathologie Biologie, vol.60, issue.4, pp.223-228, 2012.
DOI : 10.1016/j.patbio.2012.05.008

H. Autorité and D. Santé, has-sante.fr/portail/jcms/c_434715/fr/guide-d- analyse-de-la-litterature-et-gradation-des-recommandations

V. Sibaud and E. Vigarios, Toxicit??s orales des th??rapies cibl??es anticanc??reuses, M??decine Buccale Chirurgie Buccale, vol.21, issue.3, pp.149-155, 2015.
DOI : 10.1051/mbcb/2015025

A. Bodard, A. Hrifach, and S. Salino, Incidence of mucositis in patients with head and neck squamous cell carcinoma treated with radiotherapy plus cetuximab: a pilot study, M??decine Buccale Chirurgie Buccale, vol.18, issue.3
DOI : 10.1051/mbcb/2012020

M. Kuten-shorrer, E. Hochberg, and S. B. Woo, Lichenoid Mucosal Reaction to Rituximab, The Oncologist, vol.19, issue.10, pp.12-13, 2014.
DOI : 10.1634/theoncologist.2014-0169

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200996

I. Gavrilovic, Y. Balagula, and A. C. Rosen, Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment, The Oncologist, vol.17, issue.2, pp.274-278, 2012.
DOI : 10.1634/theoncologist.2011-0198

C. Gordon, Y. Rojavin, and M. Patel, A Review on Bevacizumab and Surgical Wound Healing, Annals of Plastic Surgery, vol.62, issue.6, pp.707-716, 2009.
DOI : 10.1097/SAP.0b013e3181828141

K. Sharma and J. Marcus, Bevacizumab and Wound-Healing Complications, Annals of Plastic Surgery, vol.71, issue.4, pp.434-474, 2013.
DOI : 10.1097/SAP.0b013e31824e5e57

X. Zhang, I. Hamadeh, and S. Song, Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS), Journal of Bone and Mineral Research, vol.2013, issue.2, pp.1-5, 2015.
DOI : 10.1002/jbmr.2693

A. Khan, A. Morrison, and D. A. Hanley, Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus, Journal of Bone and Mineral Research, vol.37, issue.9, pp.3-23, 2015.
DOI : 10.1016/S1359-6349(10)70055-

W. Qi, L. Tang, and A. He, Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials, International Journal of Clinical Oncology, vol.28, issue.2, pp.403-410, 2014.
DOI : 10.1007/s10147-013-0561-6

A. Boquete-castro, G. Gomez-moreno, and J. Calvo-guirado, Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, Clinical Oral Implants Research, vol.99, issue.3
DOI : 10.1111/clr.12556

T. Van-den-wyngaert, K. Wouters, H. M. Vermorken, and J. B. , RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer, pp.2035-2040, 2011.

V. Guarneri, D. Miles, N. Robert, and V. Diéras, Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer, Breast Cancer Research and Treatment, vol.25, issue.18S, pp.181-188, 2010.
DOI : 10.1007/s10549-010-0866-3

URL : https://hal.archives-ouvertes.fr/hal-00535451

G. Lescaille, A. Coudert, and V. Baoroun, Clinical stady evaluating the effect of bevacizumab on the severity of zoledronic-acid releted osteonecrosis of the jaw in the cancer patients, Bon58, pp.103-107, 2014.

N. Ngamphaiboon, J. Frustano, and E. Kossoff, Osteonecrosis of the jaw: dental autcomes in metastatic breast cancer patients traited with bisphosphonates with/without bevacizumab. Cancer Breast, pp.252-259, 2011.

F. Francini, A. Pascucci, and E. Francini, Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab, The Journal of the American Dental Association, vol.142, issue.5, 2011.
DOI : 10.14219/jada.archive.2011.0220

N. Ohga, Y. Yamazaki, K. Tsuboi, and Y. Kitagawa, Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: A case report and hypothesis, Quintessence International. Oral medecine.V, vol.46, issue.7, 2015.

J. Malan, K. Ettinger, E. Naumann, and R. Beirre, The relationship of denosumab pharmacology and osteonecrosis of the jaw. Medical management and pharmacologie update, p.114, 2012.

T. You, K. Lee, S. Lee, and W. Park, Denosumab-related osteonecrosis of the jaw: a cas reportand management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol, pp.1-6, 2015.

P. Diz, J. L. López-cedrún, and J. Arenaz, Denosumab-related osteonecrosis of the jaw, The Journal of the American Dental Association, vol.143, issue.9, 2012.
DOI : 10.14219/jada.archive.2012.0323

O. 'halloran, M. Boyd, N. Smith, and A. , Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases, Australian Dental Journal, vol.72, issue.5 Suppl, pp.516-519, 2014.
DOI : 10.1111/adj.12217

S. Olate, F. Uribe, and F. Martinez, Osteonecrosis of the jaw in patient with denosumab therapy, Int J Clin Exp Med, vol.7, issue.10, pp.3707-3709, 2014.

K. Taylor, L. Middlefell, and K. D. Mizen, Osteonecrosis of the jaws induced by anti-RANK ligand therapy, British Journal of Oral and Maxillofacial Surgery, vol.48, issue.3, pp.221-223, 2010.
DOI : 10.1016/j.bjoms.2009.08.030

T. Aghaloo, A. Felsenfend, and S. Tetrdis, Osteonecrosis of the Jaw in a Patient on Denosumab, Journal of Oral and Maxillofacial Surgery, vol.68, issue.5, pp.959-963, 2012.
DOI : 10.1016/j.joms.2009.10.010

S. Picardo, S. Kuypers, and J. Merkesteyn, Denosumab osteonecrosis of the mandibule. A new entity? A cas raport Journal of cranio-maxillo-facial surgery, pp.4165-69, 2013.

T. Aghaloo, D. S. Mallaya, and S. , Stage 0 Osteonecrosis of the Jaw in a Patient on Denosumab, Journal of Oral and Maxillofacial Surgery, vol.72, issue.4, pp.702-716, 2014.
DOI : 10.1016/j.joms.2013.09.008

G. Bettini, S. Blandamura, G. Saia, and A. Bedogni, Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process, Case Reports, vol.2012, issue.oct22 1, p.10, 2012.
DOI : 10.1136/bcr-2012-007284

U. Disel, A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit, Oral Oncology, vol.48, issue.2, pp.2-3, 2012.
DOI : 10.1016/j.oraloncology.2011.07.030

A. Santos-silva, R. G. De-castro-junior, and G. , Osteonecrosis of the mandible associated with bevacizumab therapy, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol.115, issue.6, pp.32-36, 2013.
DOI : 10.1016/j.oooo.2013.02.001

C. Estilo, M. Fornier, and A. Farooki, Osteonecrosis of the Jaw Related to Bevacizumab, Journal of Clinical Oncology, vol.26, issue.24, 2008.
DOI : 10.1200/JCO.2007.15.5424

S. Katsenos, C. Christophylakis, and K. Psathakis, Osteonecrosis of the jaw in a patient with advaced non-small cell.lung cancer receiving bevacizumab, Arch.Bronconeumol, vol.2012, issue.6, pp.48-216

D. Pakosch, D. Papadimas, and J. Munding, Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab, Oral and Maxillofacial Surgery, vol.11, issue.4, pp.303-306, 2013.
DOI : 10.1007/s10006-012-0379-9

S. Ruggiero, T. Dodson, and J. Fantasia, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw?2014 update, J Oral Maxillofac Surg, issue.10, pp.721938-56, 2014.

R. Marx, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, Journal of Oral and Maxillofacial Surgery, vol.61, issue.9, pp.1115-1122, 2003.
DOI : 10.1016/S0278-2391(03)00720-1

H. Katsarelis, N. Shah, and D. Dhariwal, Infection and Medication-related Osteonecrosis of the Jaw, Journal of Dental Research, vol.15, issue.5966, pp.534-539, 2015.
DOI : 10.1038/nature01658

O. Ristow, C. Gergrob, M. Schaiger, B. Hahlweg-majert, and V. Kehl, Effect of antiresorptive drugs on body turnover in the jaw: dénosumab compared with biphoshonates, British Journal of Oral and Maxillofacial Surgery, pp.52-308, 2014.

D. Chappard, E. Legrand, and P. Massin, Pathophysiologie des métastases osseuses, Prog Urol, vol.13, pp.9-17, 2003.

S. Barillé-nion, B. Barlogie, and R. Bataille, Advances in Biology and Therapy of Multiple Myeloma, Hematology, vol.2003, issue.1, pp.248-278, 2003.
DOI : 10.1182/asheducation-2003.1.248